|
1
|
Negri FV, Musolino A, Naldi N, Bortesi B,
Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni
G, et al: Role of immunoglobulin G fragment C receptor
polymorphism-mediated antibody-dependant cellular cytotoxicity in
colorectal cancer treated with cetuximab therapy. Pharmacogenomics
J. 14:14–19. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ,
Park YS, Park JO, Kim SY, Kim TY, Kim JH, et al: Oxaliplatin,
fluorouracil, and leucovorin versus fluorouracil and leucovorin as
adjuvant chemotherapy for locally advanced rectal cancer after
preoperative chemoradiotherapy (ADORE): An open-label, multicentre,
phase 2, randomised controlled trial. Lancet Oncol. 15:1245–1253.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS and
Chen G: The effect of COX-2 inhibitor on capecitabine-induced
hand-foot syndrome in patients with stage II/III colorectal cancer:
A phase II randomized prospective study. J Cancer Res Clin Oncol.
137:953–957. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe
HL, Wingo PA, Jemal A, Ward E, Anderson RN and Edwards BK: Annual
report to the nation on the status of cancer, 1975–2000, featuring
the uses of surveillance data for cancer prevention and control. J
Natl Cancer Inst. 95:1276–1299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ogata-Kawata H, Izumiya M, Kurioka D,
Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H,
et al: Circulating exosomal microRNAs as biomarkers of colon
cancer. PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nouraee N and Calin GA: MicroRNAs as
cancer biomarkers. Microrna. 2:102–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cohen S and Flescher E: Methyl jasmonate:
A plant stress hormone as an anti-cancer drug. Phytochemistry.
70:1600–1609. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheong JJ and Choi YD: Methyl jasmonate as
a vital substance in plants. Trends Genet. 19:409–413. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsumura H, Akimoto M, Kiyota H, Ishii Y,
Ishikura H and Honma Y: Gene expression profiles in differentiating
leukemia cells induced by methyl jasmonate are similar to those of
cytokinins and methyl jasmonate analogs induce the differentiation
of human leukemia cells in primary culture. Leukemia. 23:753–760.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishii Y, Kiyota H, Sakai S and Honma Y:
Induction of differentiation of human myeloid leukemia cells by
jasmonates, plant hormones. Leukemia. 18:1413–1419. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pu Z, Zhang X, Chen Q, Yuan X and Xie H:
Establishment of an expression platform of OATP1B1 388GG and 521CC
genetic polymorphism and the therapeutic effect of tamoxifen in
MCF-7 cells. Oncol Rep. 33:2420–2428. 2015.PubMed/NCBI
|
|
13
|
Mihajlovic M, Vlajkovic S, Jovanovic P and
Stefanovic V: Primary mucosal melanomas: A comprehensive review.
Int J Clin Exp Pathol. 5:739–753. 2012.PubMed/NCBI
|
|
14
|
Milrot E, Jackman A, Kniazhanski T, Gonen
P, Flescher E and Sherman L: Methyl jasmonate reduces the survival
of cervical cancer cells and downregulates HPV E6 and E7, and
survivin. Cancer Lett. 319:31–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ezekwudo D, Shashidharamurthy R, Devineni
D, Bozeman E, Palaniappan R and Selvaraj P: Inhibition of
expression of anti-apoptotic protein Bcl-2 and induction of cell
death in radioresistant human prostate adenocarcinoma cell line
(PC-3) by methyl jasmonate. Cancer Lett. 270:277–285. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JH, Lee SY, Oh SY, Han SI, Park HG,
Yoo MA and Kang HS: Methyl jasmonate induces apoptosis through
induction of Bax/Bcl-XS and activation of caspase-3 via ROS
production in A549 cells. Oncol Rep. 12:1233–1238. 2004.PubMed/NCBI
|
|
17
|
Gharpure KM, Chu KS, Bowerman CJ, Miyake
T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN,
Rahhal TB, et al: Metronomic docetaxel in PRINT nanoparticles and
EZH2 silencing have synergistic antitumor effect in ovarian cancer.
Mol Cancer Ther. 13:1750–1757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deb G, Thakur VS and Gupta S: Multifaceted
role of EZH2 in breast and prostate tumorigenesis: Epigenetics and
beyond. Epigenetics. 8:464–476. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsang DP and Cheng AS: Epigenetic
regulation of signaling pathways in cancer: Role of the histone
methyltransferase EZH2. J Gastroenterol Hepatol. 26:19–27. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferraro A, Boni T and Pintzas A: EZH2
regulates cofilin activity and colon cancer cell migration by
targeting ITGA2 gene. PLoS One. 9:e1152762014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bryant RJ, Cross NA, Eaton CL, Hamdy FC
and Cunliffe VT: EZH2 promotes proliferation and invasiveness of
prostate cancer cells. Prostate. 67:547–556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Ma ZB, Li K and Guo GH:
Association between EZH2 polymorphisms and colorectal cancer risk
in Han Chinese population. Med Oncol. 31:8742014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS,
Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, et al: EZH2-mediated
concordant repression of Wnt antagonists promotes
β-catenin-dependent hepatocarcinogenesis. Cancer Res. 71:4028–4039.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Xiang W, Wang M, Huang T, Xiao X,
Wang L, Tao D, Dong L, Zeng F and Jiang G: Methyl jasmonate
sensitizes human bladder cancer cells to gambogic acid-induced
apoptosis through down-regulation of EZH2 expression by miR-101. Br
J Pharmacol. 171:618–635. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Slaby O, Svoboda M, Michalek J and Vyzula
R: MicroRNAs in colorectal cancer: Translation of molecular biology
into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mirnezami AH, Pickard K, Zhang L, Primrose
JN and Packham G: MicroRNAs: Key players in carcinogenesis and
novel therapeutic targets. Eur J Surg Oncol. 35:339–347. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng HB, Zheng XG and Liu BP: miRNA-101
inhibits ovarian cancer cells proliferation and invasion by
down-regulating expression of SOCS-2. Int J Clin Exp Med.
8:20263–20270. 2015.PubMed/NCBI
|
|
28
|
Jiang W, Gu W, Qiu R, He S, Shen C, Wu Y,
Zhang J, Zhou J, Guo Y, Wan D, et al: miRNA-101 suppresses
epithelial-to-mesenchymal transition by targeting HMGA2 in
pancreatic cancer cells. Anticancer Agents Med Chem. 16:432–439.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Strillacci A, Valerii MC, Sansone P,
Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello
F, Campieri M and Spisni E: Loss of miR-101 expression promotes
Wnt/β-catenin signalling pathway activation and malignancy in colon
cancer cells. J Pathol. 229:379–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
